The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients
المؤلفون المشاركون
Maoujoud, Omar
Ahid, Samir
Dkhissi, Hocein
Oualim, Zouhair
Cherrah, Yahia
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-12-30
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Introduction.
The aim of this study was to compare the cost-effectiveness of continuous erythropoietin receptor activator (CERA) once monthly to epoetin beta (EpoB) thrice weekly to maintain haemoglobin (Hb) within the range 10.5–12 g/dL.
Methods.
Prospective cohort study and cost-effectiveness analysis.
Chronic haemodialysis patients (CHP), being treated with EpoB, were selected for two periods of follow-up: period 1, maintaining prior treatment with EpoB, and period 2, conversion to CERA once monthly.
Hb concentrations and costs were measured monthly.
Health care payer perspective for one year was adopted.
Results.
75 CHP completed the study, with a mean age of 52.9 ± 14.3 years.
Baseline Hb was 11.14 ± 1.18 g/dL in EpoB phase and 11.46 ± 0.79 g/dL in CERA phase; we observed a significant increase in the proportion of patients successfully treated (Hb within the recommended range), 65.3% versus 70.7%, p : 0.008, and in the average effectiveness by 4% (0.55 versus 0.59).
Average cost-effectiveness ratios were 6013.86 and 5173.64$, with an ICER CERA to EpoB at −6457.5$.
Conclusion.
Our health economic evaluation of ESA use in haemodialysis patients suggests that the use of CERA is cost-effective compared with EpoB.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Maoujoud, Omar& Ahid, Samir& Dkhissi, Hocein& Oualim, Zouhair& Cherrah, Yahia. 2015. The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients. Anemia،Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1053778
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Maoujoud, Omar…[et al.]. The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients. Anemia No. 2015 (2015), pp.1-9.
https://search.emarefa.net/detail/BIM-1053778
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Maoujoud, Omar& Ahid, Samir& Dkhissi, Hocein& Oualim, Zouhair& Cherrah, Yahia. The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients. Anemia. 2015. Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1053778
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1053778
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر